These benefits, together with a former report demonstrating that a small-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like conduct in mice,2 guidance the notion of targeting ACKR3 as a unique approach to modulate the opioid process, which could open new therapeutic avenues for opioid-related disorders. These outcomes propose that conolidine is https://stevey899mco7.wikifiltraciones.com/user